Af­ter tout­ing Gazy­va's po­ten­tial in lu­pus, Roche nabs 'break­through' ahead of PhI­II

Roche’s ef­fort to in­tro­duce its blood can­cer drug Gazy­va to the im­munol­o­gy space just got a boost from the FDA.

Reg­u­la­tors have grant­ed break­through des­ig­na­tion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER